SCHOTT Pharma inaugurates expanded vial production in Lebanon

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs – from biologics and other complex injectable therapies to vaccines and emergency room medications. The new capabilities feature state-of-the-art technology for efficient manufacturing and optimized output. The over 60 million USD investment was largely funded by the Biomedical Advanced Research and Development Authority (BARDA) to strengthen the resilience of the U.S. pharmaceutical supply chain and ensure reliable domestic production of critical primary packaging. The expansion significantly increases the site’s annual production capacity for core vials, while more than tripling local capacity for high-value solutions.

“The expansion contributes to SCHOTT Pharma’s long-term global growth strategy, with a strong local-for-local presence in the U.S. and scaled manufacturing capacity for high-value solutions that address key trends in the pharmaceutical industry, such as biologic medications and novel drug formulations”, says Christian Mias, CEO of SCHOTT Pharma.

In addition to installing a significant number of new high-end converting lines for core borosilicate glass vials, the expansion in Lebanon included major infrastructure modernization, line upgrades, and new state-of-the-art technology to increase the capacity for high-value solutions. 

“We would like to express our sincere gratitude to the Biomedical Advanced Research and Development Authority for supporting the expansion of our U.S.-based manufacturing footprint. With its new advanced equipment, our site in Pennsylvania is strengthening supply chain resilience in the U.S. and ensuring the availability of primary packaging for critical life-saving therapies for patients throughout our nation,“ says Christopher Cassidy, President SCHOTT Pharma USA.